Addendum—I do not see MYL being a party to the kind of Copaxone settlement discussed in this thread because I don’t think MYL’s ANDA will get FDA approval before the patents in question expire.
On a recent webcast, MYL’s CEO, Robert Coury, implored analysts to focus not on FDA approval of MYL’s ANDA, but rather on the machinations in the patent case. This, IMO, was Coury’s way of signaling that FDA approval is unlikely without having to explicitly acknowledge it.
News 
Market Data 
Discover 
AI
